Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926904 | 0.83 | TAAR1 (0.56) | TAAR1LMNAAOC3CA1CA2 | |
| SCHEMBL3257217 | 0.80 | TAAR1 (0.52) | TAAR1LMNAAOC3CA1CA2 | |
| SCHEMBL31452193 | 0.80 | TAAR1 (0.52) | TAAR1LMNAAOC3CA1CA2 | |
| SCHEMBL776466 | 0.80 | TAAR1 (0.52) | TAAR1LMNAAOC3KMT2AALDH1A1 | |
| SCHEMBL8526001 | 0.80 | TAAR1 (0.75) | TAAR1LMNAAOC3ALDH1A1DAO | |
| SCHEMBL51098 | 0.79 | LMNA (0.52) | TAAR1LMNAAOC3CA1CA2 | |
| SCHEMBL30409980 | 0.79 | LMNA (0.52) | TAAR1LMNAAOC3CA1CA2 | |
| SCHEMBL777720 | 0.78 | TAAR1 (0.50) | TAAR1LMNAAOC3CA1CA2 | |
| SCHEMBL25435653 | 0.78 | TAAR1 (0.57) | TAAR1CA1CA2IDO1MPO | |
| Hydrochloric Acid SCHEMBL20502511 | 0.78 | LMNA (0.50) | TAAR1LMNAAOC3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| CN-101263133-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | TAAR1 1568/4885LMNA 1509/4885AOC3 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.